Your browser is no longer supported. Please, upgrade your browser.
Settings
ESPR Esperion Therapeutics, Inc. daily Stock Chart
ESPR [NASD]
Esperion Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.74 Insider Own2.60% Shs Outstand27.42M Perf Week2.12%
Market Cap1.39B Forward P/E- EPS next Y-2.63 Insider Trans43.09% Shs Float24.98M Perf Month1.10%
Income-68.30M PEG- EPS next Q-1.85 Inst Own- Short Float21.57% Perf Quarter17.25%
Sales145.40M P/S9.55 EPS this Y-8.10% Inst Trans2.55% Short Ratio9.25 Perf Half Y9.40%
Book/sh6.52 P/B7.77 EPS next Y-21.10% ROA-35.70% Target Price86.08 Perf Year25.54%
Cash/sh8.33 P/C6.08 EPS next 5Y28.30% ROE-48.60% 52W Range36.06 - 60.99 Perf YTD10.07%
Dividend- P/FCF- EPS past 5Y-17.90% ROI- 52W High-16.99% Beta1.82
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin- 52W Low40.40% ATR1.87
Employees76 Current Ratio3.90 Sales Q/Q- Oper. Margin- RSI (14)56.19 Volatility3.36% 3.63%
OptionableYes Debt/Eq0.00 EPS Q/Q277.10% Profit Margin-47.00% Rel Volume0.29 Prev Close51.01
ShortableYes LT Debt/Eq0.00 EarningsMay 08 Payout- Avg Volume582.24K Price50.63
Recom2.00 SMA201.22% SMA507.58% SMA2008.56% Volume166,676 Change-0.74%
May-29-19Downgrade Goldman Neutral → Sell
May-06-19Upgrade BofA/Merrill Underperform → Neutral
Apr-26-19Upgrade Goldman Sell → Neutral $50
Mar-13-19Upgrade JP Morgan Underweight → Neutral $38 → $47
Jan-07-19Reiterated Needham Strong Buy $94 → $114
Dec-13-18Initiated Goldman Sell $45
Oct-29-18Upgrade Northland Capital Market Perform → Outperform
Oct-16-18Initiated BTIG Research Buy $82
Aug-17-18Upgrade Citigroup Neutral → Buy
Jul-11-18Downgrade Northland Capital Outperform → Market Perform
May-03-18Downgrade JP Morgan Neutral → Underweight $41
May-02-18Downgrade BofA/Merrill Buy → Underperform
Mar-27-18Reiterated Chardan Capital Markets Neutral $75 → $100
Feb-21-18Reiterated Needham Strong Buy $81 → $94
Jan-22-18Downgrade Citigroup Buy → Neutral
Jan-18-18Initiated Credit Suisse Outperform $103
Jan-17-18Reiterated UBS Buy $62 → $88
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Dec-14-17Upgrade Needham Buy → Strong Buy $72 → $81
Dec-06-17Reiterated Chardan Capital Markets Neutral $20 → $75
Jun-19-19 10:40AM  Have Insiders Been Buying Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares This Year? Simply Wall St.
Jun-07-19 09:30AM  Esperion Therapeutics (ESPR) Down 5.6% Since Last Earnings Report: Can It Rebound? Zacks
May-30-19 04:15PM  Esperion Announces the Appointment of Tracy M. Woody to Board of Directors GlobeNewswire
May-29-19 04:23PM  Biotech Stocks Clobbered As Two Slammed With Sell Ratings Investor's Business Daily
May-28-19 07:00AM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
May-27-19 06:00AM  Esperion Aims for the First Approved Non-Statin Cholesterol Reducer MoneyShow
May-10-19 08:00AM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
May-09-19 06:00AM  Esperion Gets a Go-Ahead from the FDA MoneyShow
May-08-19 08:35AM  Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Surpass Estimates Zacks
07:25AM  Esperion Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results GlobeNewswire
May-07-19 05:30AM  Esperion to Host Analyst and Investor Day Event on May 30 GlobeNewswire
May-06-19 04:15PM  A Single Rival Caused 2 Biopharma Stocks To Slip Here's Why Investor's Business Daily +11.56%
01:30PM  Here's Why Esperion Therapeutics Shares Rocketed 11.5% Higher Today Motley Fool
10:33AM  Small-Cap Biotech Esperion Surges On FDA Acceptance Of Cholesterol Drug Applications Benzinga
May-05-19 05:00PM  Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review GlobeNewswire
May-02-19 02:41PM  Heres What Hedge Funds Think About Esperion Therapeutics, Inc. (ESPR) Insider Monkey
Apr-24-19 02:12PM  Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors PR Newswire
Apr-07-19 10:45PM  Weekly CEO Buys Highlight GuruFocus.com
Apr-02-19 04:30PM  Esperion to Present at the Needham & Company 18th Annual Healthcare Conference GlobeNewswire +8.04%
Apr-01-19 07:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $200,000 of Shares GuruFocus.com
04:15PM  Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results GlobeNewswire
Mar-30-19 09:30AM  Esperion Therapeutics (ESPR) Down 12.9% Since Last Earnings Report: Can It Rebound? Zacks
Mar-21-19 07:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $217,400 of Shares GuruFocus.com
Mar-18-19 09:20AM  Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions GlobeNewswire
Mar-14-19 09:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $243,650 of Shares GuruFocus.com -8.47%
Mar-13-19 05:05PM  Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine GlobeNewswire +7.55%
Mar-12-19 07:19AM  Did You Miss Esperion Therapeuticss (NASDAQ:ESPR) Impressive 225% Share Price Gain? Simply Wall St.
Mar-05-19 08:25AM  New Research Coverage Highlights Advance Auto Parts, AxoGen, Encana, Federal Signal, Nelnet, and Esperion Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-04-19 04:30PM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
08:00AM  Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions GlobeNewswire
Mar-01-19 09:39AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4 Zacks
Feb-28-19 04:30PM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
07:00AM  Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet GlobeNewswire
Feb-22-19 05:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.39%
Jan-29-19 08:45AM  Update in Lawsuit for Investors in NASDAQ: ESPR shares against Esperion Therapeutics, Inc. announced by Shareholders Foundation GlobeNewswire
Jan-11-19 09:16AM  For Esperion Therapeutics, 2019 Could Be a Big Year Motley Fool
Jan-07-19 07:15AM  Update: Lawsuit for Investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced by Shareholders Foundation ACCESSWIRE
02:00AM  Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet PR Newswire
Jan-06-19 10:00AM  All the Pre-JPM News Healthcare Investors Need to Know Motley Fool
Jan-04-19 04:34PM  Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today Motley Fool -6.12%
07:20AM  Esperion to receive $300 million in upfront payments in deal with Daiichi Sankyo MarketWatch
07:00AM  Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe GlobeNewswire
Jan-02-19 04:15PM  Esperion to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-19-18 10:28PM  Is Esperion Therapeutics, Inc. (ESPR) A Good Stock To Buy? Insider Monkey
Nov-14-18 08:52AM  Do Options Traders Know Something About Esperion (ESPR) Stock We Don't? Zacks -7.42%
Nov-10-18 08:15AM  Esperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018 GlobeNewswire
Nov-09-18 07:50AM  Report: Exploring Fundamental Drivers Behind American Vanguard, Pioneer Natural Resources, American States Water, Groupon, Esperion Therapeutics, and Paylocity Holding New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -6.79%
Nov-08-18 08:44AM  What's Next for Esperion Therapeutics' Cholesterol-Lowering Drug Motley Fool
08:00AM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
06:00AM  3 Biotech Stocks Poised for Big Rebounds Investopedia
Nov-01-18 04:05PM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results GlobeNewswire +9.93%
Oct-31-18 02:27PM  Esperion CEO on safety of new cholesterol drug CNBC Videos +6.44%
Oct-29-18 07:43AM  Esperion stock surges 15% on late-stage results for cholesterol drug MarketWatch
Oct-28-18 05:10PM  Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumulative Results GlobeNewswire
05:00PM  Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid GlobeNewswire
Oct-26-18 08:00AM  Today's Research Reports on Trending Tickers: Gilead Sciences, Inc. and Esperion Therapeutics, Inc. ACCESSWIRE +13.22%
Oct-20-18 07:01AM  3 Top Healthcare Stocks to Buy in October Motley Fool
Oct-18-18 05:00PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Oct-17-18 08:10AM  New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-09-18 08:45AM  Do Options Traders Know Something About Esperion (ESPR) Stock We Don't? Zacks
Sep-13-18 08:52AM  Are Options Traders Betting on a Big Move in Esperion (ESPR) Stock? Zacks
Sep-02-18 09:33AM  3 Biotech Stocks That Could Soar in September Motley Fool
Aug-28-18 10:27AM  Esperion (ESPR) Combination Regimen Lowers Bad Cholesterol Zacks
Aug-27-18 10:22AM  Esperion's combo therapy lowers cholesterol level by 35 pct, shares surge Reuters
08:11AM  Esperion announces positive results for cholesterol-lowering therapy MarketWatch
07:32AM  Esperion says combo therapy lowers cholesterol level by 35 pct Reuters
07:00AM  Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study GlobeNewswire
Aug-26-18 03:40PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results Benzinga
Aug-25-18 05:45AM  Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at the European Society of Cardiology Congress GlobeNewswire
Aug-23-18 08:42AM  Are Options Traders Betting on a Big Move in Esperion (ESPR) Stock? Zacks
Aug-20-18 07:45AM  Market Trends Toward New Normal in Esperion Therapeutics, Oxford Immunotec Global, Limoneira, R1 RCM, Carbonite, and Shenandoah Telecommunications Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Aug-19-18 12:00PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Earnings Benzinga
Aug-13-18 09:00PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Aug-10-18 04:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-02-18 07:51AM  Esperion Therapeutics: 2Q Earnings Snapshot Associated Press +6.64%
07:00AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-16-18 07:45AM  Insider Buys Of The Week: Energen, Esperion Therapeutics And International Flavors Benzinga
Jul-10-18 08:55AM  Options Traders Expect Huge Moves in Esperion Therapeutics (ESPR) Stock Zacks -5.27%
Jul-06-18 10:51AM  UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ESPR, ORA, MFGP, FLR, and REPH GlobeNewswire
Jul-05-18 05:23PM  Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the Firm GlobeNewswire
04:35PM  DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
02:00PM  CLASS ACTION UPDATE for ESPR, SYMC, and PPG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
08:00AM  24 HOUR DEADLINE NOTICE: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact the Firm Business Wire
Jul-03-18 02:40PM  FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire +7.78%
08:30AM  Esperion to Host Analyst and Investor Day Event on July 10 GlobeNewswire
Jul-02-18 04:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ESPR ACCESSWIRE
04:16PM  DEADLINE REMINDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
01:22PM  Beaten-down biotech stocks Gilead, Esperion are ready for a bounce MarketWatch
01:03PM  SHAREHOLDER ALERT LC ESPR INWK FLEX KLIC SYMC MFGP FLR REPH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
09:20AM  KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for Esperion Therapeutics, Inc. Investors - ESPR ACCESSWIRE
08:00AM  FINAL DEADLINE NOTICE: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact the Firm GlobeNewswire
Jun-30-18 11:00AM  FINAL DEADLINE ALERT: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact the Firm ACCESSWIRE
09:28AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ESPR ACCESSWIRE
Jun-29-18 01:58PM  CLASS ACTION UPDATE for ESPR, PPG and PCG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:30PM  DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Jun-28-18 06:38PM  KESSLER TOPAZ MELTZER & CHECK, LLP: Important Deadline Reminder for Esperion Therapeutics, Inc. Investors ACCESSWIRE
04:46PM  UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LC, ESPR, and MFGP GlobeNewswire
02:40PM  IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
10:34AM  SHAREHOLDER ALERT MOH ESPR PPG ANW QCOM UNM COOL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAYLEBEN TIMOTHY MPresident & CEOMar 29Buy40.005,000200,00061,163Apr 01 04:41 PM
MAYLEBEN TIMOTHY MPresident & CEOMar 20Buy43.485,000217,40056,163Mar 21 05:01 PM
VITULLO NICOLEDirectorMar 19Sale44.7315,329685,5960Mar 21 09:02 AM
MAYLEBEN TIMOTHY MPresident & CEOMar 14Buy48.735,000243,65051,163Mar 14 04:57 PM
BIOTECH TARGET N V10% OwnerMar 14Buy49.8950,0002,494,3553,522,964Mar 15 07:50 PM
NEWTON ROGER SDirectorMar 12Sale50.0625,0001,251,500548,726Mar 14 04:57 PM
BIOTECH TARGET N V10% OwnerJan 04Buy41.2980,0003,303,2563,472,964Jan 07 05:10 PM
BIOTECH TARGET N V10% OwnerDec 24Buy39.9150,0001,995,7253,392,964Dec 26 11:44 AM
BIOTECH TARGET N V10% OwnerDec 17Buy47.7360,0002,864,0703,342,964Dec 19 01:14 PM
Boxer Capital, LLC10% OwnerNov 05Sale57.1660,0003,429,8431,101,250Nov 05 07:56 PM
Boxer Capital, LLC10% OwnerNov 02Sale55.2140,0002,208,5001,161,250Nov 05 07:56 PM
NEWTON ROGER SDirectorNov 02Sale50.7622711,523573,726Nov 02 05:00 PM
NEWTON ROGER SDirectorNov 01Sale50.012,600130,026573,953Nov 02 05:00 PM
NEWTON ROGER SDirectorOct 18Sale50.001005,000576,553Oct 18 05:05 PM
NEWTON ROGER SDirectorOct 17Sale50.0212,673633,903576,653Oct 18 05:05 PM
NEWTON ROGER SDirectorOct 16Sale50.019,400470,094589,326Oct 18 05:05 PM
NEWTON ROGER SDirectorAug 27Sale51.0517,700903,610598,726Aug 29 04:56 PM
NEWTON ROGER SDirectorAug 17Sale50.067,300365,438616,426Aug 22 07:18 AM
BIOTECH TARGET N V10% OwnerAug 03Buy46.1450,0002,306,9703,282,964Aug 06 03:23 PM
BIOTECH TARGET N V10% OwnerJul 12Buy41.7750,0002,088,3003,232,964Jul 13 11:45 AM
BIOTECH TARGET N V10% OwnerJun 29Buy39.4850,0001,973,8053,182,964Jul 03 11:55 AM
BIOTECH TARGET N V10% OwnerJun 21Buy38.5760,0002,314,2243,132,964Jun 25 12:43 PM